SLE

This early-phase study tests a new treatment called RD06-05, which uses specially engineered immune cells (CAR-T cells) to target and calm overactive immune responses in people with autoimmune diseases like lupus, multiple sclerosis, and vasculitis. The main goal is to check safe…

This early-stage study tests a new drug, CLN-978, in 24 people with moderate to severe lupus. The goal is to see if it is safe and can help control the disease by reducing certain immune cells. Participants receive the drug as a shot under the skin.

This study tests a treatment called CART19 for teens and young adults (ages 12-29) with severe lupus that hasn't improved with standard care. The treatment uses a patient's own immune cells, modified to target and calm the overactive immune system causing lupus. The goal is to co…

This early-phase study tests whether a new drug, ONTO1, is safe and tolerable for people with lupus nephritis or systemic lupus erythematosus (SLE). Researchers will give ONTO1 alongside standard lupus treatments to 61 adults and look for side effects and signs of symptom improve…

This early-stage study tests a single injection of stem cells from donated umbilical cords in 10 adults with active lupus. The goal is to see if the treatment is safe and can reduce disease activity and improve kidney function. Participants continue their usual medications and ar…

This study tests whether an experimental drug called VENT-03 can reduce skin symptoms in people with cutaneous lupus (CLE), with or without systemic lupus (SLE). About 24 adults will receive either VENT-03 or a placebo for 4 weeks, then all will receive VENT-03 for 8 more weeks. …

This study is testing a new drug called APG-2575 in 40 people with mild-to-moderate lupus. The main goal is to see if the drug is safe and how the body processes it. Participants will receive either the drug or a placebo, and researchers will monitor for side effects and measure …

This early-stage study tests a new treatment called RD06-05, which uses specially engineered immune cells to target and calm overactive immune responses in people with autoimmune diseases like lupus, vasculitis, and scleroderma. Up to 84 adults aged 18 to 75 will receive the ther…

This early-stage study tests a new drug, SAR448501/DR-0201, in 62 adults with lupus or rheumatoid arthritis. The goal is to find the safest and most effective dose by checking side effects and how the drug works in the body. Participants will be followed for about 13 months, and …

This study looks back at the pregnancy history of 50 women who were later diagnosed with lupus. The goal is to find out how often pregnancy problems like miscarriage or preterm birth happen before the lupus diagnosis. By understanding these early signs, doctors may be able to spo…